X
KEY PRODUCTS KEY SERVICES
Details:
This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the GelMEDIX pipeline.
Lead Product(s): Regenerative Medicine,Hyaluronic Acid
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: GelMEDIX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2022
Details:
As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eirion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
HTL Biotechnology is the world leader in the responsible development and production of pharmaceutical-grade biopolymers.
